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initiation of the immune response seems to take place.
These findings from a murine GN model suggest that the
transfer of in vitro expanded autologous Treg might rep-
resent a new treatment option in human GN.
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Aldosterone-mediated
endothelial remodeling and
oxidative stress
To the Editor: The recognition of the inflamma-
tory and profibrotic role of aldosterone in the patho-
physiology of cardiovascular disease, via its effect on
endothelial dysfunction, is of growing importance, as
demonstrated by the results of the recently concluded
Randomized Aldactone Evaluation Study (RALES)
[1], and the EPlerenone neuroHormonal Efficacy and
SUrvival Study (EPHESUS) [2]. These studies have,
in fact, indicated the reduction of aldosterone effects
through receptor blocking as additional benefit to pa-
tients with cardiovascular diseases.
In a paper published in the May issue Kidney Inter-
national, Oberleithner documented “in vitro” an aldos-
terone remodeling effect on human endothelium through
induction of cell stiffness due to a presumably aldosterone
induced oxidative stress via modulation of NAD(P)H ox-
idase [3]. We would like to provide further support to the
contention of a specific remodeling and profibrotic ac-
tion of aldosterone with the demonstration “ex vivo” in
human mononuclear cells, recently published by our lab-
oratory [4], that indicates that aldosterone has a direct
effect on oxidative stress through its ability to increase
the levels of p22phox, an important subunit of NADPH
oxidase, essential for superoxide anion generation. It, in
fact, functions as an integral subunit of the final electron
transport from NADPH to heme and molecular oxygen in
generating superoxide anions. The aldosterone-induced
increased level of PAI-1, a recognized profibrotic protein,
we have shown in the same study [4], may also provide a
direct link to the cardiovascular profibrotic and remod-
eling action of aldosterone. Our findings were further
strengthened by similar effects shown by glycyrrhetinic
acid [4], a constituent of licorice root, which is known to
have a direct mineralocorticoid-like effect [5]. Thus, the
report of Oberleithner [3] in combination with the results
of our study provides clear evidence for the aldosterone-
related vascular remodeling effects through its induction
of oxidative stress and oxidative stress-related profibrotic
molecules, such as PAI-1 [4].
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Screening for
microalbuminuria
In their recent contributions to Kidney International,
de Zeeuw [1], as well as de Jong and Brenner [2], argue
that primary prevention of cardiovascular and renal dis-
ease may be possible by lowering albumin excretion in
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subjects with microalbuminuria. Others even advocate
screening of the general population for albuminuria as a
means to prevent renal and generalized vascular diseases
[3]. We feel that the currently available data do not allow
the recommendation of such a policy. It is true that in-
creased levels of albumin excretion are independently as-
sociated with the subsequent development of renal insuf-
ficiency, as well as with cardiovascular morbidity and mor-
tality. Furthermore, reduction of proteinuria, especially
by blockade of the renin-angiotensin system (RAS), has
been shown to slow the progression of renal damage in
diabetic and nondiabetic renal disease. However, in sub-
jects with microalbuminuria and normal renal function,
favorable renal effects of RAS blockade have only been
reported for diabetics [4]. Likewise, the only study thus
far demonstrating a beneficial effect of reduction of al-
buminuria on cardiovascular outcome was performed in
type 2 diabetics [5]. To support the use of albuminuria as a
target for primary prevention in a much broader popula-
tion, the abovementioned authors refer to a recently pub-
lished study of Asselbergs et al [6]. In this study, subjects
with microalbuminuria that were recruited by screening
of the general population were randomized to fosino-
pril or matching placebo and to pravastatin or match-
ing placebo. The results of this study are quoted by de
Zeeuw as “Asselbergs et al have indeed shown that ACE
inhibitors offer cardiovascular protection in subjects that
have no other risk factors than increased amounts of al-
bumin in their urine.” A similar conclusion was drawn by
de Jong and Brenner. However, a closer look at the data
of Asselbergs et al reveals that this interpretation is not
justifiable. First, the effect of fosinopril on the primary
cardiovascular end point was not statistically significant,
and hard conclusions are, therefore, not allowed. A post-
hoc subgroup analysis suggested that especially subjects
with an albuminuria level of over 50 mg/24 hr might ben-
efit from treatment with an ACE inhibitor, but this sub-
group regarded not even 25% of all individuals. Second,
treatment with fosinopril only reduced the incidence of
cerebrovascular events, while there was no decrease in
any other cardiovascular end point. This disagrees with
other prevention studies that consistently show a parallel
risk reduction for all types of cardiovascular events [7–
10]. Moreover, treatment with fosinopril did not affect
the progression rate of carotid intima-media thickness
[11], while the latter is an accepted surrogate marker for
the development of stroke [12]. Notably, the incidence of
cerebrovascular events in the patients not treated with
fosinopril was 6 per 1000 person-years This is very high
when compared with reported incidences of 1.5 to 2.1 per
1000 person-years in other low-risk populations [13, 14],
and nearly equals the incidence of stroke observed in type
2 diabetics [10]. In fact, the methods section indicates that
severe headache for >24 hours without any other abnor-
mality was considered a cerebrovascular accident. In view
of all these discrepancies, the type of events that occurred
in the control group should be known exactly, to rule out
the possibility that ACE inhibition merely reduced the
incidence of (severe) headache [15]. Finally, even when
considering the effect of ACE inhibition on all end points,
the number needed to treat is 38 for four years (i.e., 152
patient-years) to prevent one event, which in our view
indicates that it is questionable whether screening and
subsequent treatment of microalbuminuria will be cost
effective.
In conclusion, we think that it is appropriate to regard
microalbuminuria as an important risk marker for cardio-
vascular and renal disease. At present, the value of reduc-
ing microalbuminuria has only been proven in diabetic
patients. As long as the positive effect of therapy in nondi-
abetic microalbuminuric patients has not been firmly es-
tablished, additional studies, including cost-effectiveness
analysis, have to be performed before a plea for the im-
plementation of large-scale screening campaigns for mi-
croalbuminuria is justified.
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